KPC Pharmaceuticals
Research and development, production, and marketing of botanical drugs.
Launch date
Employees
Market cap
$1.3b
Enterprise valuation
$1.1b (Public information from Sep 2024)
Share price
CNY12.2 600422.SS
Kunming Yunnan (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.7b | 8.3b | 8.3b | 7.7b | 8.5b | 9.8b | 10.8b |
| % growth | (5 %) | 7 % | - | (7 %) | 10 % | 15 % | 10 % |
| EBITDA | 704m | 902m | 823m | 906m | 930m | 1.1b | 1.3b |
| % EBITDA margin | 9 % | 11 % | 10 % | 12 % | 11 % | 12 % | 12 % |
| Profit | 457m | 508m | 383m | 445m | 583m | 757m | 912m |
| % profit margin | 6 % | 6 % | 5 % | 6 % | 7 % | 8 % | 8 % |
| EV / revenue | 0.8x | 1.0x | 1.3x | 2.0x | 1.3x | 1.1x | 1.0x |
| EV / EBITDA | 9.3x | 9.3x | 13.0x | 17.5x | 11.7x | 9.5x | 8.1x |
| R&D budget | 128m | 101m | 69.7m | 71.3m | - | - | - |
| R&D % of revenue | 2 % | 1 % | 1 % | 1 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about KPC Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
